Consistent with this, CLL patients with ATM abnormalities (11q deletion and/or ATM mutations) display higher refractoriness to DNA-damaging drugs, such as alkylating agents and fludarabine [6–8]. This evidence concerns the gene ATM and B-cell chronic lymphocytic leukemia.